10-Q: TuHURA Biosciences Reports Q1 2025 Financial Results, Cites Ongoing Merger with Kineta and Phase 3 Trial Preparations

TuHURA Biosciences announced its financial results for the first quarter of 2025, highlighting ongoing preparations for a Phase 3 trial of IFx-2.0 and the pending merger with Kineta, Inc.

Summary

• TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing personalized cancer vaccine product candidates.
• The company is preparing to initiate a Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to Keytruda for advanced or metastatic Merkel cell carcinoma.
• TuHURA is also developing bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells (MDSCs).
• The company completed a reverse merger with Kintara Therapeutics, Inc. on October 18, 2024.
• TuHURA is in the process of merging with Kineta, Inc., with the merger expected to close in the second quarter of 2025.
• The aggregate cash component of the Kineta merger consideration is a base amount of $6,005,000.
• The aggregate share component of the Kineta merger consideration consists of up to approximately 3,998,053 shares of TuHURA common stock.
• TuHURA incurred a net loss of $6.7 million for the three months ended March 31, 2025, compared to a net loss of $4.8 million for the same period in 2024.
• Research and development expenses were $4.6 million for the three months ended March 31, 2025, compared to $3.6 million for the same period in 2024.
• As of March 31, 2025, TuHURA had cash and cash equivalents of $6.2 million.
• The company expects its existing capital resources, including anticipated payment of Warrant Exercise Notes, will be sufficient to fund planned future operations into the late fourth quarter of 2025.
• The company expects to raise cash through the sale of preferred shares, common shares, debt issuances, obtaining grants, or commercial partnerships.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress with its clinical trials and merger plans, it is also facing increasing losses and the need for additional funding. The uncertainty around the Kineta merger and the company's ability to continue as a going concern tempers any positive outlook.

Positives

• TuHURA has a Special Protocol Assessment agreement with the FDA for its Phase 3 trial of IFx-2.0.
• The company is developing innovative approaches to cancer immunotherapy, including personalized vaccines and antibody-drug conjugates.
• The Kineta merger is expected to bring additional assets and capabilities to TuHURA.
• The company anticipates that existing capital resources will be sufficient to fund planned future operations into the late fourth quarter of 2025.

Negatives

• TuHURA incurred a net loss of $6.7 million in Q1 2025, an increase from the $4.8 million loss in Q1 2024.
• The company has an accumulated deficit of $117.8 million as of March 31, 2025.
• TuHURA expects to continue to incur operating losses.
• The company needs to raise additional capital to fund its operations and growth strategy.
• There is substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• The Kineta merger is conditional on TuHURA raising $20 million in gross proceeds.

Risks

• The company's ability to fund planned operations for the next twelve months and its ability to continue as a going concern are uncertain.
• The company's ability to obtain, maintain, and protect its intellectual property rights is a risk.
• The company's ability to complete the merger with Kineta, Inc. and realize the anticipated benefits is not guaranteed.
• The cost, timing, scope, and results of the company's clinical studies are subject to uncertainty.
• The company's ability to retain the continued service of its key professionals and to identify, hire, and retain additional qualified professionals is a risk.
• Existing regulations and regulatory developments in the United States and other jurisdictions could impact the company.
• Government laws, general economic and market conditions, inflation, and imposition of new or revised global tariffs could affect the company.
• Developments relating to the company's competitors and its industry could impact the company.
• The therapeutic potential of IFx-Hu 2.0, IFx-Hu 3.0 and future product candidates is uncertain.

Future Outlook

TuHURA expects to continue to incur operating losses and will need substantial additional funding to support its continuing operations and pursue its growth strategy. The company anticipates that existing capital resources, including anticipated payment of the Warrant Exercise Notes, will be sufficient to fund the company's planned future operations into the late fourth quarter of 2025. The Kineta Merger Agreement provides that it is a condition to the closing of the Kineta Merger that TuHURA complete a financing transaction resulting in no less than $20 million in gross proceeds.

Management Comments

• Management based projections of operating capital requirements on our current operating plan, which includes several assumptions that may prove to be incorrect, and we may deplete our available capital resources sooner than management expects.

Industry Context

TuHURA operates in the competitive immuno-oncology space, focusing on novel approaches to cancer immunotherapy. The company's focus on overcoming resistance to checkpoint inhibitors aligns with a significant unmet need in the field. The ongoing legislative and executive actions regarding pharmaceutical pricing could impact the company's future revenue potential.

Comparison to Industry Standards

• It is difficult to compare TuHURA's financial results directly to industry standards due to its clinical-stage nature and lack of product revenue.
• Comparable companies in the immuno-oncology space include Adaptimmune Therapeutics, BioNTech, and Gritstone Bio, all of which are focused on developing novel cancer immunotherapies.
• These companies often have high R&D expenses and net losses as they advance their product candidates through clinical trials.
• TuHURA's cash position of $6.2 million is relatively low compared to some of its peers, highlighting the need for additional funding.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by the company's financial situation and need to raise additional capital.
• Patients with Merkel cell carcinoma could benefit from the development of IFx-2.0.
• Suppliers and creditors face the risk of delayed payments or potential financial difficulties if the company's financial situation does not improve.

Next Steps

• Initiate Phase 3 trial of IFx-2.0 for Merkel cell carcinoma.
• Complete the merger with Kineta, Inc.
• Secure additional funding through equity offerings, debt financings, or collaborations.
• Continue development of IFx-Hu3.0 and other product candidates.

Key Dates

Keywords

immuno-oncology, cancer vaccine, IFx-2.0, Kineta merger, clinical trial, Merkel cell carcinoma, antibody-drug conjugates, research and development, financial results, TuHURA Biosciences